26 psychiatric pharmacotherapy update9.17.14& continuing education conference by the university...
TRANSCRIPT
9.17.14
C O N T I N U I N G E D U C A T I O N C O N F E R E N C E B Y T H E U N I V E R S I T Y O F T E X A S A T A U S T I N C O L L E G E O F P H A R M A C Y
26th annual
PSYCHIATRIC PHARMACOTHERAPY UPDATE October 23 & 24, 2014 • Austin, Texas
THURSDAY, 23RD OF OCTOBER 2014 7:00 -‐ 7:45 CONTINENTAL BREAKFAST Ballroom Lobby
7:45 -‐ 8:00 Welcome and Opening Remarks Stephen R. Saklad, Pharm.D., BCPP Psychiatric Pharmacotherapy Update Conference Chair
All presentations take place in the Ballroom
8:00 -‐ 9:00 Psychotropic New Drug Update Stephen R. Saklad, Pharm.D., BCPP Clinical Associate Professor, College of Pharmacy, The University of Texas at Austin
• Describe the pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs recently marketed as well as drugs approaching the market
• List key trends in new drug development
9:00 -‐ 10:00 PTSD Treatment Approaches Update Alan Peterson, Ph.D., ABPP Professor, Deputy Chair for Military Collaboration UT Health Science Center San Antonio
• Describe current trends for treatment of non-‐combative PTSD • Examine the differences between combative and non-‐combative
treatment regiments for PTSD
10:00 -‐ 10:15 BREAK Refreshments in Ballroom Lobby
10:15 -‐ 10:45 Schizophrenia Update Troy Moore, Pharm.D., MS Pharm, BCPP Clinical Pharmacy Specialist South Texas Veterans Health Care System
• Describe potential functional gains demonstrated by atypical antipsychotics
• Cite evidence supporting the cognitive benefits of antipsychotics
10:45 -‐ 11:15 Clozapine Medicaid Data Karen L. Rascati, Ph.D. Professor of Health Outcomes & Pharmacy Practice College of Pharmacy, The University of Texas at Austin
• Describe data summarizing current trends in treatment for schizophrenia
• Describe current data in relation to the use of clozapine
11:15 -‐ 11:45 What Comes After Clozapine? Troy Moore, Pharm.D., MS Pharm, BCPP
• Explain alternative treatments of Schizophrenia • Describe cognitive therapy approaches in relation to
pharmacotherapy treatments
11:45 -‐ 12:15 Panel Discussion on Schizophrenia Treatment Troy Moore, Pharm.D., MS Pharm, BCPP Karen L. Rascati, Ph.D.
• Discuss various current trends in treatments and alternative treatments
12:15 -‐ 1:00 LUNCH Buffet in Ballroom Lobby, Seating in Rooms Across Hall
1:00 -‐ 2:00
Diversity of Psychiatric Pharmacotherapy: Treatment Differences Between Ethnic Groups Y. W. Francis Lam, Pharm.D., FCCP Professor of Pharmacology UT Health Science Center San Antonio
• Describe the effect of genetics on psychotropic disposition and response
• Identify cultural factors that influence mediation use • Discuss the scope of cultural and diversity competency
2:00 -‐ 3:00
Pediatric Psychopharmacology: The Surge in Autism Dillip Karnik, MD Medical Director for Pediatric Neurology Dell Children’s Medical Center of Central Texas
• Describe data / trends in surge of autism diagnosis in TX / US • Discuss pharmacotherapy treatments • Discuss cognitive education stimulation and other cognitive
treatment trends
3:00 -‐ 3:15 BREAK Refreshments in Ballroom Lobby
3:15 -‐ 4:15 Pediatric Psychopharmacology Update M. Lynn Crismon, Pharm.D., BCPP Dean & Professor, College of Pharmacy The University of Texas at Austin
• Describe recent advances in pediatric psychopharmacology • Discuss recent advances in pharmacotherapy for youth with
mental disorders • Delineate current controversies with regard to the use of
psychotropic medications in youth
4:15 -‐ 5:15 Geriatric Psychopharmacology Update Jason E. Schillerstrom, MD Director of Psychiatric Residency Training University of Texas Health Science Center San Antonio
• Describe recent advances in geriatric psychopharmacology • Discuss recent advances in pharmacotherapy for elderly with
mental disorders
5:15 -‐ 6:30 RECEPTION Dover’s Room
9.17.14
C O N T I N U I N G E D U C A T I O N C O N F E R E N C E B Y T H E U N I V E R S I T Y O F T E X A S A T A U S T I N C O L L E G E O F P H A R M A C Y
FRIDAY, 24TH OF OCTOBER 2014 7:00 -‐ 7:45 CONTINENTAL BREAKFAST Ballroom Lobby
7:45 -‐ 8:00 Welcome and Announcements Stephen R. Saklad, Pharm.D., BCPP Psychiatric Pharmacotherapy Update Conference Chair
• Identify paradigm shifts in the assessment / treatment of bipolar disorder
• Describe new treatment strategies in the treatment of bipolar disorder
8:00 -‐ 9:00
Antidepressants in Bipolar Disorder Patients with Depression Charles L. Bowden, MD Clinical Professor of Psychiatry & Pharmacology Nancy U. Karren Endowed Chair of Psychiatry University of Texas Health Science Center San Antonio
• Describe effective strategies for assessment of patients with characteristics indicative of bipolar depression
• List the clinical consequences of anxiety associated with bipolar disorders
• Identify differences in effectiveness of interventions for bipolar depression
• Describe combination regimen drug treatments for bipolar depression
9:00 -‐ 10:00
Medical Marijuana Update (CME Ethics Credit) Igor Grant, PhD Distinguished Professor and Chair Department of Psychiatry University of California San Diego School of Medicine
• Describe the evidence for medical use of cannabis • Discuss untoward effects of the use of medical marijuana • Discuss ethical issues regarding use of cannabis
10:00 -‐ 10:15 BREAK Refreshments in Ballroom Lobby
10:15 -‐ 11:15
Old Drugs, New Drugs: Changing Patterns of Use and Abuse (CME Ethics Credit) Jane Maxwell, Ph.D. Senior Research Scientist, Addiction Research Institute Center for Social Work Research The University of Texas at Austin
• Describe the emerging drugs (both new ones and emergence of old drugs) and changes over time
• Discuss treatment options and the need to get creditable information on harms out concerning these new drugs
• Discuss ethical dilemmas practitioners face when a patients substitutes illegal substances for prescription drugs
11:15 -‐ 12:15
Misuse of Legal Prescription Drugs (CME Ethics Credit) Thomas Kosten, MD JH Waggoner Chair & Professor of Psychiatry, Neuroscience, Pharmacology, Immunology, & Pathology Baylor Medical School Houston
• Describe trends resulting in additions to prescription drugs • Discuss methods to avoid addiction • Discuss treatment options to end addiction • Describe ethical issues in trends with prescription drug addiction
12:15 -‐ 12:30 WORKING LUNCH Pick up lunch in ballroom lobby and Return to ballroom for lunchtime panel
12:30 -‐ 1:30 Ethics and Issues of Addiction Panel (CME Ethics Credit) Thomas Kosten, MD Jane Maxwell, Ph.D. Igor Grant
• Identify the various ethical issues facing practitioners in the treatment of addiction
• Discuss the similarities of behaviors leading to addiction among various mental disorders, and similarities in treatments
1:30 -‐ 2:30
Medication Management for Patients with Psychiatric Disorders in Primary Care Carla Cobb, Pharm.D., BCPP University of Montana
• Describe a patient-‐centered, team approach to mental health care in primary care
• Design an evidence-‐based medication regimen that fits the individual patient's needs
• Evaluate the medication regimen to ensure that it is appropriate, effective, safe, and convenient
2:30 -‐ 3:30 Dementia Update Rajesh Tampi, MD, MS, FAPA Associate Professor of Psychiatry UT Health Science Center San Antonio
• Describe recent changes and trends in the treatment of dementia • Discuss alternatives to antipsychotic therapy • Describe side effects, Black Box Warnings, and other risks
associated with antipsychotic therapy
3:30 -‐ 3:45 CE EVALUATION / CLOSING REMARKS
CME Ethics Credit: This event has been approved by the Texas Department of State Health Services, Continuing Education Service for 4 credits in medical ethics and/or professional responsibility